Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20473280 | 1.00 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL17244393 | 0.93 | KDM4E (0.35) | ALDH1A1SMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL1539510 | 0.91 | KDM4E (0.38) | ALDH1A1SMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL30238446 | 0.91 | KDM4E (0.38) | ALDH1A1SMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL20473318 | 0.91 | ADRA1A (0.35) | KDM4EMAPTADRA1A | |
| SCHEMBL13862616 | 0.90 | — | — | |
| SCHEMBL24127683 | 0.90 | ADRA1A (0.36) | ALDH1A1SMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL18513428 | 0.89 | KDM4E (0.35) | ALDH1A1SMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL13862617 | 0.88 | KDM4E (0.35) | ALDH1A1SMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL1539482 | 0.88 | KDM4E (0.35) | ALDH1A1SMN1; SMN2KDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312511-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-11-01 | — | — | US | disclosed |
| EP-3363801-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017101808-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312511-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | GABRA5, GABRA1, GABRA6 | ALDH1A1 464/4885SMN1; SMN2 3525/4885KDM4E 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.